HHS peptide compounding policy lets pharmacies make BPC 157 and five other peptides

WASHINGTON. A new federal peptide compounding policy lets licensed pharmacies make six unapproved peptides, including BPC 157, without facing enforcement action, according to a Department of Health and Human Services document posted this week. The peptide compounding policy is temporary, sets ten conditions and approves none of the six as a medicine. It covers BPC 157, epitalon, KPV, MOTS c, Semax and TB 500. Men's Health reported that the FDA announced the step on Wednesday, Oct. 28. FDA scientists had advised against broad access in July, citing missing human safety and efficacy data.

What the HHS enforcement discretion covers

The document sets out what HHS calls enforcement discretion for the six peptide ingredients. Until a final rule decides whether each one belongs on the 503A bulks list, HHS said it does not intend to act against a state licensed pharmacy, a federal facility or a licensed physician that compounds with them. That list normally decides which ingredients without a USP monograph or an approved drug behind them a pharmacy may use. The policy gives no end date. The National Community Pharmacists Association told members that no timeframe was given and that pharmacies still await final rulemaking. HHS said it may revisit the policy, in whole or in part, if a safety signal or a product quality problem emerges with a compounded product.

The ten conditions appear in the HHS policy document. The raw peptide must come from an FDA registered maker with a certificate of analysis showing identity, purity and potency, plus tests for endotoxins, heavy metals and microbes. Pharmacies must report what they compound, along with serious adverse events and quality problems, to the FDA MedWatch program and to the states involved. Each product may hold only one active ingredient and must carry the label line "This is a compounded drug product. Not for resale." Any oral version needs records showing adequate absorption in humans. The only device allowed in the pack is an FDA cleared syringe. A valid prescription for a named patient is still required, as federal compounding law already demands.

How the Pharmacy Compounding Advisory Committee vote led here

The Pharmacy Compounding Advisory Committee met on July 23 and 24 to weigh seven peptides for the 503A bulks list, according to the FDA meeting page. The pharmacists association reported that the panel backed the six now covered and rejected a seventh, emideltide, also known as delta sleep inducing peptide. The table below shows the use the FDA reviewed for each of the six and the forms the new policy allows. The reviewed uses and the allowed forms are separate questions. BPC 157, for example, was assessed for ulcerative colitis, while the policy covers injectable, oral and topical versions. The policy also limits Semax to nasal use and KPV to topical and oral forms.

HHS documents show the FDA drug center, known as CDER, recommended against listing all six peptides, yet the committee voted in favor of each one, and HHS has now sided with the committee.

HHS documents show the FDA drug center, known as CDER, recommended against listing all six peptides, yet the committee voted in favor of each one, and HHS has now sided with the committee. Each peptide sat in an FDA interim group called Category 2 from September 2023 until April 22, 2026. HHS gave three reasons for each ingredient. It said use is now documented and counted, that new lot test certificates fill gaps CDER had flagged, and that the policy conditions manage the remaining risk. For several peptides, HHS described the CDER safety concerns as mechanistic or inferential rather than observed. The document cites a placebo controlled trial of a MOTS c analogue that reported no serious adverse events.

BPC 157 compounding rests on thin human evidence

BPC 157 compounding draws the most attention, but none of the six has passed the human testing the FDA requires for approval, Men's Health reported. The HHS document itself states that compounded drugs are not FDA approved and that the agency does not check their safety, effectiveness or quality before sale. Thomas Kremen, a UCLA Health physician who recently reviewed the evidence on six popular peptides with colleagues, told Men's Health that recommending them is "probably not a strong stance." Asked whether doctors could tell patients that BPC 157 heals tissue, he answered, "Maybe if they're talking about a rat in some study." Abud Bakri, a California hospital physician who has used BPC 157 himself, said he cannot yet fully explain the risks of some of these compounds to patients.

Claims about where these peptides come from are also disputed. Men's Health reported that the American Academy of Peptide Medicine, a group founded last year, filed a white paper to the FDA docket describing BPC 157 and epitalon as made naturally by the body. Vince Luca of the Moffitt Cancer Center in Florida said no gene coding for BPC 157 has been found in the 35 years since it was isolated from gastric juice. He said natural origin would not prove safety anyway. Terry Roberts of Brunel University of London said he knows of no study showing epitalon in humans. Luca's team plans basic tests on human cells in the coming months. The academy did not answer questions on its claim, Men's Health said.

Gray market peptides and what comes next

HHS framed the step as a safety measure aimed at gray market peptides. The document says the policy should discourage wide use of research use only peptides from foreign makers, which it said pose a safety risk to U.S. patients, and that it advances patient choice while protecting safety. Advocates at a September conference in Washington made a similar case for licensed pharmacies and physician oversight, Men's Health reported. Critics see the reverse risk. A recent JAMA Viewpoint on the vote argued that the move could undercut the drug approval system. Mislabeled products remain a separate hazard: customs tests in Iceland found many seized peptide vials did not contain what their labels claimed.

What happens next depends on rulemaking. HHS said public comments may give the FDA more evidence to weigh, and a final rule will decide whether each peptide joins the 503A bulks list or is left off. Until then, the peptide compounding policy can be narrowed or withdrawn if safety or quality problems appear in MedWatch reports. Demand may not shift quickly. Two people with chronic pain who used BPC 157 and TB 500 told Men's Health that compounded versions cost more than gray market supply and are not covered by insurance. A third user said he developed lasting numbness and an autoimmune condition after taking BPC 157, though a causal link has not been established. Background on why BPC 157 sat outside pharmacies explains the earlier rules.

Conclusion

Readers should treat the peptide compounding policy as a temporary enforcement choice, not an approval. HHS let pharmacies compound six unapproved peptides under ten conditions while the FDA finishes rulemaking, despite advice from its own drug reviewers against listing them. Human evidence for BPC 157 and the other five remains limited, and HHS said it can reverse course if safety signals appear. The next markers are the final rule and any adverse event reports from pharmacies. This report is for research context only and is not medical advice.